Computational BioMedicine Laboratory

LOCCANDIA

Category: european

Project Title: Lab On Chip based protein profiling for Cancer Dia

Funding Organization: EC

Programme: FP6-2005-IST-5-No 034202

Programme Nature: Micro/ nano based subsystems

Coordinator: ATOS Origin S.A.E

Partners: CEA, UoM, SIB, Biovision,Genebio,FORTH

Duration: 01/06/2006-31/05/2009

Expiration Date: 2009

Total Budget: 627.500 Euro

FORTH ICS budget: 233.880 Euro

Project Objective: The human plasma proteome holds the promise of a revolution in disease diagnosis and therapy. One major breakthrough should come from the detection of multi-protein disease markers including isoforms. The LOCCANDIA project targets the integration of a full proteomics analysis chain, from blood sample to the diagnosis information, combining bio-, nano, and information-related technologies. It includes an innovative patented lab-on-chip developed at CEA. The clinical application is early pancreatic cancer diagnosis. The project is based on: *a jury of three identified proteins, *a protein isolation protocol *an optimised chromatographic-electrospray lab-on-chip, and *an Integrated Clinico-Proteomics Environment - including a Proteomic Information Management System, a Clinical Information System, and data-analysis modules (for preprocessing, reconstruction, visualisation, and protein identification) based on advanced data mining and knowledge discovery operations targeting the linkage between clinical and proteomic data and the discovery of clinico-proteomic knowledge. The clinical validation is applied to a cohort of 92 pancreatic-cancer patients. Our targeted performances are: (a) to get at least the sensitivity of an orthogonal ELISA approach, (b) to operate the analysis chain in less than 12 hours, and (c) to demonstrate the interest of multi-protein marker. The main research outcomes will be an optimised chromatographic-electrospray lab-on-chip, a software environment supporting the integrated device, a proof-of-concept of their application to protein profiling for cancer diagnosis and an exploitation plan. The roadmap of this 36 months project is defined according to three main milestones: *At month 12, a first protein profile using a first version of the lab-on-chip on artificial samples is available. *At month 24, all the final versions of the sub-systems are ready for integration and validation. *At month 33, the validation on clinical samples is completed. The consortium partnership involves partners over five countries, combining basic and applied research (CEA, FORTH, SIB, WWU), one large company (ATOS) and two SMEs (DBVN, GENEBIO), including clinicians and end-users (WWU, DBVN).

© Copyright 2007 FOUNDATION FOR RESEARCH & TECHNOLOGY - HELLAS, All rights reserved.